Pulmolisa – providing early answers
Approximately two thirds of lung cancer cases are diagnosed at late stages, when surgical removal is no longer possible, significantly reducing the chance of survival.
The early detection of lung cancer at asymptomatic stages increases survival. The Pulmolisa test of Biosystems is a multiplex ELISA that detects early changes in blood protein features (epitope panel) that indicate the likelihood of lung cancer. The test only requires a simple blood sample that is then processed in a designated laboratory.
Biosystems has obtained a CE mark for the Pulmolisa test for in vitro diagnostics from the OGYEI (The Hungarian regulatory authority)
